ABSTRACT
Objective To investigate the efficacy and safety of low-dose and standard-dose intravenous alteplase for acute ischemic stroke. Methods The patients with acute ischemic stroke treated with intravenous alteplase from August 2012 to January 2016 were analyzed retrospectively. According to the dosage of the drug, the patients were divided into either a low-dose group (0. 6-0. 8 mg/kg) or a standard-dose group (0. 9 mg/kg). The efficacy was evaluated with the modified Rankin Scale (mRS) at 90 days, and a favorable functional outcome was defined as mRS 0-1. The safety was evaluated by the mortality at 90 days and the incidence of symptomatic intracerebral hemorrhage (SICH) within 7 d after onset. Results A total of 790 patients were enrolled, including 612 in the low-dose group and 178 in the standard-dose group. There was no significant difference in each baseline clinical data between the 2 groups. Compared with the standard-dose group, there was no significant difference in the good outcome rate of the small-dose group at day 90 (35. 6% vs. 37. 6% ; χ2 = 0. 872, P = 0. 35) and mortality (5. 1% vs. 6. 2% ;χ2 = 2. 173, P = 0. 14), but the incidence of SICH was significantly lower (1. 8% vs. 5. 1% ; χ2 = 5. 875, P =0. 015). Conclusion The efficacy of low-dose intravenous alteplase for acute ischemic stroke is equivalent to the standard-dose and the safety is better.
ABSTRACT
Objective: This study aims to observe the clinical efficacies of hyper-early low-dose alteplase thrombolysis in treating acute ischemic stroke [AIS]
Methods: Two hundred twenty AIS patients were randomly divided into group A [90 cases], group B [90 cases], and group C [40 cases]. The National Institutes of Health Stroke Scale [NIHSS] scores, mRS score-evaluated prognosis, intracranial hemorrhage, and mortality of the three groups were observed before and after the treatment
Results: The NIHSS scores of the three groups were significantly reduced after the treatment [P<0.05], among which the NIHSS score of group A was the lowest [P<0.05]; and the difference between group B and C was not significant [P>0.05] The incidence of such complications as cerebral hemorrhage in the three groups was low, and there was no significant difference among the groups [P>0.05]. The modified Rankin Scale [mRS] scores of the three groups showed that group A had much better prognosis than group B and C, while the difference between group B and group C was not significant
Conclusions: The hyper-early low-dose alteplase thrombolysis was safe and effective in Acute ischemic stroke [AIS]